TOP TIERMARKET NEWSWIRE
Movers explained · October 8, 2026

Why Is PACIRA BIOSCIENCES I (PCRX) Stock Up Today?

By the Top Tier Newswire AI Desk · reviewed against 11 wire stories

PACIRA BIOSCIENCES I (PCRX) is up +44.05% in the latest session. Our newswire has captured 11 stories on PCRX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

The written analysis for PCRX publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.

PCRX by the numbers

Last: $36.30Session: +44.05%7 sessions: -0.75%Coverage: 11 stories / 8 sourcesAI sentiment: 62/100 (bullish)
PCRX · today's session (5-min) · +44.01% vs prior close · updated 9:52 AM ET
$24.53$30.79$37.05prev close $25.20$36.297:25 AM8:01 AM8:37 AM9:13 AM9:50 AM7:25 AM · $25.728:15 AM · $36.388:20 AM · $36.338:25 AM · $36.358:30 AM · $36.338:35 AM · $36.348:40 AM · $36.338:45 AM · $36.348:50 AM · $36.338:55 AM · $36.349:00 AM · $36.339:05 AM · $36.339:10 AM · $36.339:15 AM · $36.339:20 AM · $36.339:25 AM · $36.329:30 AM · $36.299:35 AM · $36.309:40 AM · $36.309:45 AM · $36.309:50 AM · $36.29
AI sentiment, last 36h · averaged over 11 stories · 62/100 bullish
AI sentiment 62/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowThe Fly · sentiment 63 · Pacira price target raised to $31 from $30 at TruistThe Fly · 63Pacira price target raised to $31 from $30 at TruistPR Newswire · sentiment 67 · Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPR Newswire · 67Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy…The Fly · sentiment 64 · Viatris to acquire Pacira for $36.50 per share in cash, or $1.65BThe Fly · 64Viatris to acquire Pacira for $36.50 per share in cash, or $1.65BSeeking Alpha · sentiment 64 · Viatris to buy Pacira BioSciences for $36.50/share in cashSeeking Alpha · 64Viatris to buy Pacira BioSciences for $36.50/share in cashThe Fly · sentiment 64 · Viatris: Pacira deal expected to be immediately accretive to financial guidanceThe Fly · 64Viatris: Pacira deal expected to be immediately accretive to financial guidanceMarketChameleon · sentiment 64 · Viatris targets non-opioid pain leadership with a $1.65 billion Pacira deal and two patent-protected U.S. brands October 8, 2026MarketChameleon · 64Viatris targets non-opioid pain leadership with a $1.65 billion Pacira deal and two paten…WSJ · sentiment 64 · Viatris to Buy Pacira BioSciences for $1.65 BillionWSJ · 64Viatris to Buy Pacira BioSciences for $1.65 BillionSEC 8-K · sentiment 53 · Pacira BioSciences, Inc. (PCRX) files 8-KSEC 8-K · 53Pacira BioSciences, Inc. (PCRX) files 8-KMarketChameleon · sentiment 61 · PCRX jumps as new caregiver survey finds 78% feel unprepared to manage postsurgical pain at home October 8, 2026MarketChameleon · 61PCRX jumps as new caregiver survey finds 78% feel unprepared to manage postsurgical pain …InvestorsHub · sentiment 64 · Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy ExpansionInvestorsHub · 64Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy…
1m agoInvestorsHubBULLISH 64M&A

Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion

36m agoMarketChameleonBULLISH 61Product/PR

PCRX jumps as new caregiver survey finds 78% feel unprepared to manage postsurgical pain at home October 8, 2026

Pacira BioSciences and the Caregiver Action Network released findings from a 202-response caregiver survey showing many families feel unprepared to manage postsurgical pain at home. The results highlight demand for earlier education and detailed pain-management plans, with 78% saying caregivers are expected to manage pain without sufficient information and 72% indicating they would consider alternatives with better pre-surgery guidance.

1h agoSEC 8-KNEUTRAL 53General

Pacira BioSciences, Inc. (PCRX) files 8-K

Filed: 2026-10-08 AccNo: 0001104659-26-114571 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

1h agoWSJBULLISH 64M&A

Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company’s medicines portfolio.

2h agoMarketChameleonBULLISH 64M&A

Viatris targets non-opioid pain leadership with a $1.65 billion Pacira deal and two patent-protected U.S. brands October 8, 2026

Viatris announced an agreement to acquire Pacira BioSciences in an all-cash deal valued at $1.65 billion, aiming to expand its innovative medicines strategy and build leadership in non-opioid pain therapies. The transaction adds Pacira’s marketed U.S. brands EXPAREL and ZILRETTA, with Pacira reporting approximately $746 million in trailing revenue and $177 million in adjusted EBITDA through June 30, 2026. Viatris said the deal is expected to close by the end of 2026 and be immediately…

2h agoThe FlyBULLISH 64M&A

Viatris: Pacira deal expected to be immediately accretive to financial guidance

2h agoSeeking AlphaBULLISH 64M&A

Viatris to buy Pacira BioSciences for $36.50/share in cash

Viatris to acquire Pacira for $36.50/share in a $1.65B cash deal, expected to close by end of 2026.

2h agoThe FlyBULLISH 64M&A

Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B

2h agoPR NewswireBULLISH 67M&A

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global...

1d agoThe FlyBULLISH 63Analyst

Pacira price target raised to $31 from $30 at Truist

Frequently asked questions

Why is PCRX stock up today?

PACIRA BIOSCIENCES I (PCRX) is up +44.05% in the latest session. Our newswire has captured 11 stories on PCRX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100). The most recent driver: "Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion" (InvestorsHub).

Is PCRX a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of PCRX coverage reads 62/100 over 11 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on PCRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.